Clark Capital Management Group Inc. Purchases 95,755 Shares of Johnson & Johnson $JNJ

Key Points

• Clark Capital Management Group Inc. increased its stake in Johnson & Johnson by 23.4%, purchasing an additional 95,755 shares, bringing its total ownership to 504,799 shares valued at approximately $83.7 million.
• Johnson & Johnson recently reported quarterly earnings of $2.77 EPS, exceeding analysts' expectations of $2.68, and has set FY 2025 guidance at EPS between 10.800 and 10.900.
• The company declared a quarterly dividend of $1.30 per share, with a dividend yield of 2.9%, payable on September 9th to stockholders of record by August 26th.

Clark Capital Management Group Inc. raised its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 23.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 504,799 shares of the company's stock after buying an additional 95,755 shares during the quarter. Clark Capital Management Group Inc.'s holdings in Johnson & Johnson were worth $83,716,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Nuveen LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at about $1,369,188,000. GAMMA Investing LLC raised its holdings in shares of Johnson & Johnson by 24,450.4% during the 1st quarter. GAMMA Investing LLC now owns 7,215,367 shares of the company's stock valued at $1,196,596,000 after purchasing an additional 7,185,977 shares in the last quarter. Bank of New York Mellon Corp lifted its position in shares of Johnson & Johnson by 26.4% in the first quarter. Bank of New York Mellon Corp now owns 23,182,464 shares of the company's stock worth $3,844,580,000 after buying an additional 4,842,582 shares during the last quarter. Janus Henderson Group PLC lifted its holdings in Johnson & Johnson by 134.5% in the 4th quarter. Janus Henderson Group PLC now owns 7,948,508 shares of the company's stock worth $1,149,536,000 after purchasing an additional 4,559,147 shares during the last quarter. Finally, Pacer Advisors Inc. boosted its holdings in shares of Johnson & Johnson by 1,382.0% during the 1st quarter. Pacer Advisors Inc. now owns 3,030,084 shares of the company's stock worth $502,509,000 after buying an additional 2,825,626 shares during the period. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Stock Down 0.3%

Shares of JNJ traded down $0.57 on Friday, hitting $178.20. The company's stock had a trading volume of 9,733,095 shares, compared to its average volume of 7,556,979. The firm's fifty day moving average price is $168.57 and its 200-day moving average price is $160.76. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $181.16. The firm has a market capitalization of $429.15 billion, a price-to-earnings ratio of 19.06, a P/E/G ratio of 2.28 and a beta of 0.40.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analysts' expectations of $22.85 billion. During the same period in the previous year, the firm posted $2.82 EPS. The firm's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, equities research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is 55.61%.

Analysts Set New Price Targets

JNJ has been the subject of several recent analyst reports. Royal Bank Of Canada increased their target price on Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Guggenheim reiterated a "neutral" rating and set a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Leerink Partnrs cut shares of Johnson & Johnson from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, May 13th. Finally, UBS Group lifted their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and a consensus target price of $176.29.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business's stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company's stock, valued at $31,652,491.53. The trade was a 24.08% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders own 0.16% of the company's stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.